Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Non-Current Liabilities: 2013-2024

Historic Total Non-Current Liabilities for Capricor Therapeutics (CAPR) over the last 12 years, with Dec 2024 value amounting to $4.0 million.

  • Capricor Therapeutics' Total Non-Current Liabilities rose 242.49% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 242.49%. This contributed to the annual value of $4.0 million for FY2024, which is 17.90% down from last year.
  • Capricor Therapeutics' Total Non-Current Liabilities amounted to $4.0 million in FY2024, which was down 17.90% from $4.9 million recorded in FY2023.
  • Capricor Therapeutics' Total Non-Current Liabilities' 5-year high stood at $14.7 million during FY2022, with a 5-year trough of $3.4 million in FY2020.
  • For the 3-year period, Capricor Therapeutics' Total Non-Current Liabilities averaged around $7.9 million, with its median value being $4.9 million (2023).
  • Per our database at Business Quant, Capricor Therapeutics' Total Non-Current Liabilities surged by 152.57% in 2022 and then crashed by 66.97% in 2023.
  • Over the past 5 years, Capricor Therapeutics' Total Non-Current Liabilities (Yearly) stood at $3.4 million in 2020, then spiked by 69.07% to $5.8 million in 2021, then skyrocketed by 152.57% to $14.7 million in 2022, then crashed by 66.97% to $4.9 million in 2023, then decreased by 17.90% to $4.0 million in 2024.